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Originally discovered as a fungal extract (1), cyclosporine A (CSA)' hasproven
to be an important and interesting drug for immunologists in both clinical and
experimental settings (2). Recipients of allografted tissues and cells treated over
a limited period with CSA show a profound degree of graft survival (3-6) . Used
both experimentally in several animal models (7-13) and in some clinical situa-
tions(14-16) in humans,CSA hasbeen shown to be highly effective in preventing
or reversing several autoimmune diseases . Considerable effort over the past
decade has lead to the accumulation of much information about CSA, but at
present its mechanism ofaction on the immune system remains largely unknown,
and some enigmas remain .
As an example of one such enigma, CSA is known to be a potent suppressor
of acute allogeneic GVHD in rodent models (17) . Nevertheless, recent studies of
Glazier et al . (18) have produced the unexpected finding that irradiated rats,
reconstituted with syngeneic or autologous marrow and maintained on CSA for
6 wk, develop a fatal autoimmune syndrome soon after the drug is discontinued .
This autoimmune disease shows the same histopathologic features as allogeneic
GVHD, is mediated by T cells, and can be transferred adoptively to secondary
recipients (18) .
In the present study, we confirm the unusual findings of Glazier et al . (18)
concerning CSA-induced autoimmunity in Lewis rats . In addition, (a) we explore
the role of the thymus in this drug-induced disease process ; (b) we demonstrate
that adoptive transfers of this disease to secondary recipients canbe accomplished
with relatively few T cells from autoimmune donors, and that onset of disease
from such transfers can be blocked by cotransfers of lymphoid cells from normal
donors ; and (c) we show that the potencies of syngeneic and allogeneic reactivity
of cells from autoimmune donors are similar in popliteal lymph node assays .
Thus, aside from the potent suppressive effect CSA exerts on the immune system
in some circumstances, these data demonstrate that prolonged treatment with
CSA can lead to profound T cell-mediated autoimmunity when the drug is
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Treatment
* 7.5 mg/kg/d for 40 d.
TABLE I
CSA-induced Autoimmunity
Mortality (dead/total) and survival time (days)
Materials and Methods
Results
+CSA*
￿
-CSA
x-irradiation (1000 rad), BM
￿
11/11
￿
18, 19 (3 animals), 20,
￿
1/7
￿
27, >100 (6 animals)
(3 .0-5 .0 X 10')
￿
21 (3 animals), 24,
25, 30
x-irradiation (750 rad)
￿
5/6
￿
25, 27, 28, 30, 46
￿
0/6
￿
>100 (6 animals)
discontinued. This may provide the basis for a useful animal model for more
definitive studies of the cellular events involved in the onset and inhibition of at
least some autoimmune diseases.
Rats.
￿
Lewis (L, RT1') and (L X DA)F, hybrids (RT1'~") rats were purchased from
The Trudeau Institute (Saranac Lake, NY). These animals were used at ^-8 wk of age.
Where required, they were irradiated at 83 rad/min (Philadelphia) or 133 rad/min (La
Jolla) . Thymectomies were performed on adult animals using standard procedures (19,
20).
Autoimmune rats were prepared as described by Glazier et al . (18). This included
irradiation (1,000-1,050 rad), marrow reconstitution (2 .0-5 .0 X 10' cells) and CSA
treatment (7 .5 mg/kg/d, diluted in olive oil) subcutaneously for 6 wk. Cells were obtained
from these animals for transfer studies 10 d to 2 wk after CSA was discontinued. The
authors are grateful to Sandoz, Inc. (East Hanover, NJ) for supplies of CSA.
Cells.
￿
Suspensions of lymph node cells were prepared according to standard proce-
dures (21).
Antibodies.
￿
Monoclonal antibodies that identify various lymphocyte subsets in rats were
kind gifts of Dr. D . W. Mason, Medical Research Council Cellular Immunology Unit
(Oxford, UK), or were purchased from Accurate Chemical and Scientific Corp. (Westbury,
NY). These included W3/25 for Th cells (22). OX8 for Tk/s cells (23), and Ox12, Igk
(24). Fluorescein-conjugated rabbit F(ab')2 anti-mouse Ig and affinity-purified sheep
F(ab')2 anti-mouse Ig antibodies were purchased from Cappel Laboratories (Cochranville,
PA). These latter two exhibit some crossreactivity on rat Ig; this was minimized by using
5% rat serum in the binding reactions.
Cell Fractionation.
￿
Lymph node cells were depleted of selected subpopulations using
modifications (25) of rosetting procedures described by Parish and Hayward (26), and by
Mason (27). Contamination of purified subpopulations was monitored by FACS analysis
(25).
Local GVH Reactions.
￿
These were measured by the quantitative popliteal lymph node
weight assay (28).
CSA-induced Autoimmunity.
￿
Results of the first series of experiments (Table 1)
confirmed in a striking way the report of Glazier et al. (18). Lewis rats, 8 wk of
age, lethally irradiated (1,000 rad), reconstituted with marrow (5 .0 X 10' cells),
and given daily subcutaneous inoculations of CSA (7 .5 mg/kg) for 6 wk, devel-
oped a fatal syndrome very similar in appearance to acute GVHD. These animals
developed erythroderma of the ears, eyelids, and feet; they had swollen digits,
diarrhea, raised fur, and a hunched appearance soon (8-10 d) after the 6-wkGroup
I
￿
Sham Tx (day 1),
II
￿
Tx (day 1)
III
IV
V
VI
Treatment
SOROKIN ET AL.
TABLE 11
CSA-induced Autoimmunity:Effects of Thymectomy
x-irradiation, BM, ±CSA*
x-irradiation, BM, ±CSA
x-irradiation, BM, ±CSA, Tx (day 14)
x-irradiation, BM, ±CSA, Tx (day 28)
x-irradiation, BM, ±CSA, Tx (day 42)
x-irradiation, BM, ±CSA, sham Tx (day 42)
Mortality
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* In each case, x-irradiation was 1,000 rad; 3.0 x 10° BM cells were transferred ; and CSA was given at 7.5 mg/kg/d for 42 days, as indicated .
course of CSA injections was discontinued. Later (14-21 d), they displayed
extensive weight loss and partial alopecia. In experiments conducted with the rat
colony maintained in Philadelphia, death routinely occurred within a month,
usually early in the third week.
Table I also shows that rats given sublethal irradiation (750 rad) without
marrow reconstitution develop lethal autoimmune disease after discontinuing
CSA treatment, although somewhat more slowly.
In experiments conducted more recently in La Jolla (with rats from the same
vendor), there are some marked differences in the timing and expression of
these disease symptoms (data not shown). The early features noted above occur
in all animals (70 to date), and 70% of the animals die within a 6-wk period. The
remaining 30% of animals develop total alopecia, appear to pass a crisis point in
terms of their vitality, and then remain quite healthy, except for total hair loss
for several months, at which time this study was discontinued. Evidently, the
time of death and some of the symptoms of autoimmune disease are determined
by various conditions prevailing in different animal colonies. Thus it may be
somewhat difficult to compare results from different laboratories with endpoints
based on mortality, but it does seem clear that the early classic symptoms
(erythroderma of the ears, dermatitis, diarrhea, etc.) of acute systemic GVHD in
adult animals occur routinely and reliably within the first 2 wk after CSA
treatment is discontinued.
Fffects ofThymectomy.
￿
Table II shows the results of a studydesigned to explore
the thymus dependency of CSA-induced autoimmunity. All groups were treated
the same: irradiation (1,000 rad), marrow reconstitution, with and without CSA
treatment daily for 6 wk; the various groups differ, however, with respect to the
timing of thymectomy. Rats thymectomized immediately before irradiation and
CSA treatment (group 11) do not develop any symptoms whatsoever of autoim-
mune disease, but rats thymectomized 2 wk (group III), 4 wk (group IV), or 6
wk (on the day that CSA is discontinued, group V) develop disease, although it
is somewhat delayed in terms of onset and time of death.
These results imply that the CSA-induced autoimmune cell population origi-
nates in the thymus, and moreover, that these cells mature and exit the thymus
during the course of CSA treatment.
Source of Autoimmune Cell Precursors.
￿
Results of the previous study provide
the basis for an assay to assess the presence of CSA-inducible autoimmune
(dead/total)
+CSA -CSA
Survival time (d)
5/5 0/3 IS-30
1/12 0/5
3/5 25-60 (all animals showed disease)
5/5 25-60
5/5 0/5 25-60
5/5 0/4 18-30161 8
￿
CYCLOSPORINE A-INDUCED AUTOIMMUNITY IN RATS
TABLE III
CSA-induced Autoimmunity: Host Modifications
Deaths occurred in 18-30 d.
* In each case, x-irradiation was 1,000 rad; 3.0-5.0 X 10' BM cells were transferred; and CSA was
given at 7.5 mg/kg/d, as indicated.
precursors fromvarious sources. Animalslackinga thymus during CSA treatment
fail to develop autoimmune disease. Thus, in the experiment shown in Table
III, thymectomized, irradiated, and marrow-reconstituted animals were also
given lymphoid cells from various sources or grafted in the axilla with intact
thymus lobes from newborn syngeneic donors, and then treated with CSA as
before; only the animals given intact thymus lobes developed the disease. These
results imply that the cell population that develops autoreactivity during CSA
treatment (a) is either absent or present in insufficient numbers both in the
peripheral lymphoid pool and in normal thymocyte populations; and (b) requires
some element of an intact thymus not present in thymocyte suspensions. Evi-
dently, the autoreactive population arises from precursors that traffic to the
postirradiated or engrafted newborn thymus, and their subsequent maturation
in that organ is influenced by CSA.
Adoptive Transfer of CSA-induced Autoimmunity.
￿
The data in Fig. I provide a
comparison ofvarious cell populations obtained from CSA-induced autoimmune
donors in transferring this disease adoptively to irradiated secondary recipients .
These transfers involved various numbers ofwhole spleen and lymph node cells,
T cells (negatively depleted by rosetting procedures of class I-positive and Ig+
cells), Th cells (depleted of class II-positive, Ig+, and Tk/s cells), Tk/s cells
(depleted ofclass II-positive, Ig+, and Th cells), and B cells depleted ofTh and
Tk/s cells. These cell populations were obtained from the primary autoimmune
donors 14-21 d after CSA treatment was stopped.
Several points seem clear from these data. First there is a dose dependence in
the transfer ofthe disease. Animals receiving large numbers of whole spleen and
lymph node cell populations die within 3 wk. However, transfers of as few as 106
cells are also effective, although the recipients survive longer (4-6 wk). Second,
populations enriched for both Th and Tk cells or Th cells only are as effective
quantitatively as unseparated populations, and B cell-enriched and Tk/s-en-
riched populations are much less effective. The marginal effectiveness of the B
cell population most likely reflects its contamination with Tcells; as few as 0.3 X
Group Treatment
+CSA
Mortality
(dead/total)
-CSA
I Tx, x-irradiated, BM* 0/8 0/5
Sham Tx, x-irradiated, BM 4/4
II Tx, x-irradiated, BM, thoracic duct lymphocytes (5 .0 X 108) 0/5
Tx, x-irradiated, BM, spleen andlymph node cells (5.0 X 108) 0/6 0/5
Tx, x-irradiated, BM, thymocytes (9.0 X 108 i.v. + 9.0 X 108 i.p.) 0/5
Tx, x-irradiated, BM, thymus lobes (three per left axilla) 4/5
Sham Tx, x-irradiated, BM, thoracic duct lymphocytes (5.0 X 108) 3/310
e
22
Cells transferred (x106)
Normal donor
￿
CSA donor
a
o
__
80-100 40-60 10-20
￿
5
￿
I
￿
0.3
Number (x l06) Cells Transferred
FIGURE 1 .
￿
Adoptive transfer of lethal autoimmune disease with various numbersof unsepar-
ated spleen and lymph node cells (0), T cells depleted of OX12+ cells (A), Th cells depleted
ofOX8* and OX 12+cells (p), Tk/s cells depleted of W3/25+ andOX 12* cells(/), and Bcells
depleted of W3/25* and OX8+ cells (O). All the cell populations were monitored by FACS
analysis for contamination by depleted cell subsets; this was usually <2% and did not exceed
4%.
TABLE IV
CSA-induced Autoimmunity: Inhibition ofAdoptive Transfer with
Normal SPL/LN
Survival time ofsecondary recipi-
ents (d)
100
￿
>100 (3 animals)
10
￿
10, 12, 14, 18, 31
100
￿
10
￿
>100 (6 animals)
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106 Th cells are effective, and this could represent a 6% contamination of the B
cell preparation.
Inhibition of Autoimmunity by Cotransfer with Normal Lymphocytes.
￿
Table IV
shows that cotransfers of 10-fold excess of spleen and lymph node cells from
normal donors effectively block the onset of autoimmune disease following
adoptive transfer of 107 cells from autoimmune donors. Thus, if autoimmune
donors contain a significant number of T cells (Fig. 1), it appears that spleen and
lymph node cell populations from normal donors contain a substantial number
of some cell type that inhibits this syngeneic immune reactivity.
Comparison of Syngeneic and Alloreactivity.
￿
The finding that a lethal autoim-
mune reactivity can be adoptively transferred with relatively few T cells (Fig. 1)
implies that the relevant cell involved must be a prevalent one. In Table V, we
compare the potency of syngeneic and alloreactivity of cells form autoimmune
donors in quantitative popliteal lymph node assays. While cells from control, oil-
SOROKIN ET AL.
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TABLE V
CSA-induced Autoimmunity: Auto- and Alloreactivity of Lymphocytes
from CSA-treated Lewis Donors
* 10' donor cells injected per recipient footpad; donors in groups 11, 111,
V, and VI were irradiated (1,050 rad), marrow reconstituted, and given
CSA 7.5 mg/kg in olive oil, or olive oil only daily for 6 wk. Donor cells
were obtained 10-14 d after CSA treatment was discontinued.
treated donors show no syngeneic reactivity (6 .0 ± 1 .9 mg), they show substantial
alloreactivity (33.8 ± 14.5 mg) in L/DA recipients . By comparison, cells from
CSA-treated donors show elevated reactivity in both syngeneic (19.4 ± 7.1 mg)
and allogeneic (25.5 ± 9.8 mg) recipients of similar magnitude.
Discussion
These studiesexplore further the somewhat unexpected and enigmatic finding
(18) that when irradiated, marrow-reconstituted rats are givendaily maintenance
doses for 6 wk of CSA, a drug usually used to suppress alloreactivity and some
autoimmune conditions (3-17), they develop an acute, usually fatal, autoimmune
syndrome soon after the drug is discontinued. We report here several findings
concerning the onset of the CSA-inducedautoimmunity. First, it does not require
lethal irradiation and marrow reconstitution; sublethal irradiation and drug
treatment is also effective (Table I). This finding rules out any possibility of
genetic heterogeneity in the colony as a contributing factor, i.e., GVHD based
on inadvertent antigenic disparity between bone marrow donor and irradiated
host.
Second, the thymectomy experiments clearly indicate that development of
CSA-induced autoreactivity requires the presence of a radioresistant thymic
component (Table 11, group I vs. group 11) present also in intact thymus lobes
from newborn donors (Table 111). Autoimmune precursors appear in the postir-
radiated thymus, mature, then exit within 2 wk to the peripheral lymphocyte
pool during the course of CSA treatment (Table II, group III). There, present
in significant numbers, they evidently remain dormant in the presence of CSA
until the drug is discontinued, at which time they become activated, probably by
self-MHC class II molecules (29), and then they initiate an as yet unknown
cascade of events leading to fatal autoimmune disease.
just how CSA alters eventin the thymus leading to appearance of autoimmune
precursors, or to the failure to delete them, is not clear, and this remains a key
question in this interesting model. Cheney and Sprent (30) have suggested that
Group Donor/recipient t
combination*
Donors
(n)
Recipi-
ents (n) Poode
lymph
weigh
(mg)
I L normal --> L 5 14 4 .6 t 1 .6
1I 1. oil~L 5 15 6 .0± 1.9
I1I 1, CSA~L 9 26 19 .4± 7 .1
IV L normal ~ L/DA 4 10 69 .5 ± 38.2
V L oil --~ L/DA 5 13 33 .8 ± 14.5
VI L CSA --~ L/DA 6 13 25 .5 ± 9.8SOROKIN ET AL.
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CSA inhibits the expression of class II molecules on macrophages and/or den-
dritic cells in the thymus, thereby interfering with the normal process of self-
tolerance. The normal elimination of self-reactive clones fails to occur, allowing
the production of a significant population of nontolerant T cells that peripher-
alize and eventually cause disease. Although there are some attractive features
to this model, it may not be correct. It fails to account for the finding that
autoimmunity does not develop in CSA-treated animals if the thymus is shielded
during irradiation (18, 31).
Cheney and Sprent (30) do indicate, however, that while normal, nonirradiated
animals treated with CSA fail to show any symptoms ofautoimmunity, cells from
these donors are able to cause fatal disease when adoptively transferred to
irradiated secondary recipients . Evidently, autoimmune precursors can develop
in CSA-treated animals without irradiation, but the activity of these cells seems
to be held in check, perhaps by some kind of suppressor population .
Third, the findings in Table III deal with the question of whether CSA-
inducible autoimmune precursors occur in the normal peripheral lymphocyte
pool or in suspensions of normal thymus cells. Animals thymectomized (and
irradiated) before CSA exposure show no evidence ofautoimmunity whatsoever.
Reconstitution with thymocyte suspensions from three to four donors, splenic
and lymph node cells from two donors, or thoracic duct lymphocytes drained
from two donors fails to reveal the presence of CSA-inducible autoimmune
precursors in these populations.
Fourth, although the thymectomy studies (Tables II and III) indicate the
importance of the thymus in CSA-induced autoimmunity, adoptive transfer
studies (Fig. 1) using enriched T or B cell populations from autoimmune donors
indicate the involvement of T cells, particularly those of the helper subset, in the
effector phases of this disease. In view of the effectiveness of rather small numbers
of cells (0 .3-1 x 106) in transferring this disease, the frequency of autoreactive
cells in CSA-treated animals must be considered to be quite high.
Fifth, adoptive cotransfer experiments with lymphocytes from normal and
autoimmune donors indicate the presence of some cell type among normal
lymphocyte populations that effectively inhibits the transfer of autoreactivity in
secondary recipients. If the frequency of cells with autoreactivity is high (see
above), the proportion of suppressive cells present in the normal lymphocyte
pool that block autoreactivity must also be considered to be significant. Prelimi-
nary experiments currently in progress indicate that this suppressive cell in
normal lymph node suspensions is a T cell (Wilson, D. B., D. H. Wilson, K.
Schroder, and H. Kimura, unpublished data), but we cannot yet determine
whether it belongs to the Th or Tk/s subset.
Finally, Table V provides a comparison of auto- and alloreactivity of cells in
CSA-treated animals. Lymphocytes from autoimmune donors provoke enlarge-
ment of popliteal lymph nodes in quantitative local GVH assays in syngeneic and
F, recipients that are of the same magnitude (group III vs. group VI). Evidently,
cells with antiself reactivity are as prevalent as those with alloreactivity in
autoimmune animals.
There are marked similarities in the CSA-induced autoimmunity model and
in the systemic GVHD model. Both involve T cells of the W3/25+ subset, and1622
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they display very similar histopathologic features (22). It is therefore tempting
to consider the possibility that they share common underlying mechanisms. If
this is so, then someofour current understandingofthe detailsofthe interaction
of MHC gene products with anti-MHC receptors of alloreactive T cells in
GVHD may be directly applicable to consideration of the interaction of self
MHC gene products with autoreactive Tcells in CSA-induced autoimmunity.
Previous studies with the GVH model in rats have generated several key
findings that may be pertinent to consideration of the mechanisms of CSA-
inducedautoimmunity and self-tolerance. First, anti-MHC receptors ofalloreac-
tive T cells are themselves potent immunogens. Nonirradiated A/B F, rats
immunized with 3.0 x 107 A-strain T cells recover from very slight GVH
reactions and become specifically resistant to GVHD caused by further inocula-
tion with A-strain T cells, but they remain vulnerable to GVHD caused by B-
strain T cells (32, 33).2 The immunogenic markers appear to be anti-MHC
receptors on T cell clones having a particular allospecificity.
Second, immune A/B animals, resistant to anti-MHC' alloreactivity, remain
susceptible to anti-MHCa GVH reactions. Thus, anti-MHC Tcell receptors seem
idiotypically diverse. But A/B F, rats immunized with A-strain T cells, and thus
resistant to A anti-b alloreactivity, also resist anti-b reactivity by T cells from
third-party rat strains. Surprisingly, therefore, the idiotypic markers of T cell
receptors specific for a particular MHC antigen (e.g., MHC') behave as if they
were monomorphic in different strains (34).
Third, the GVH resistance mechanism is mediated by F, T cells; it can be
adoptively transferred to secondary F, recipients(32), and these sametransferred
cell populations contain cytotoxic T cells that can be stimulated to lyse anti-
MHC' blasts from any strain, but not anti-MHC' blasts nor cells of other
specifications (35).
These findings with the GVH model may relate to the autoimmune model in
two ways. First, as discussed above, some portion of receptors for MHC alloan-
tigens appears to be highly conserved in different rat strains; it follows that
crossreactive idiotypic determinants expressed on anti-MHC' receptors of allo-
reactive T cells from strains A, C, D, . . . , may also be expressed on self-reactive
T cells of autoimmune (e.g., strain B) rats, and that these receptors may be
immunogenic in the appropriate setting.
The second feature of T cell receptors in the GVH model relevant to the
autoimmune model is pertinent to the preceeding argument; it concerns the
surprising ease and rapidity with which parental T cells can induce GVH
resistance in F, animals. F, rats immunized with parental T cells and then
irradiated (750 rads), even as soon as 1 d later, demonstrate specific GVH
resistance to subsequent challenge with T cells from the same parental strain.
This finding suggests that a normal A/B F, rat already has clones of T cells with
specificity for anti-MHC' receptors on donor A anti-b T cells. Evidently these
can be rapidly primed; they behave as a population already expressing immuno-
logic memory. If this is so, what is the internal antigen present in the A/B F,
that drives them? It seems likely that these internal "self" antigens are the
'For simplicity, we refer to various involved strains as A, B, C, etc. having different MHC
haplotypes a, b, c, etc.receptor molecules present on anti-self-MHCb-reactive T cells in the F1 rat (36);
the same cells that are somehow deregulated in the CSA-treated autoimmune
rat. Our current studies are directed at this issue.
Summary
These studies explore the phenomenon ofcyclosporine-induced autoimmunity
in irradiated Lewis rats . We show that (a) the presence of a thymus is required,
and autoimmune precursors develop in and exit from this organ to the peripheral
lymphocyte pool within a 2-wk period after the initiation of cyclosporine treat-
ment; (b) adoptive transfers of drug-induced autoimmunity to irradiated second-
ary recipients can be accomplished with relatively few cells of the Th subset, and
these transfers of autoimmunity can be blocked by cotransfer of normal lymphoid
cells; and (c) potency estimates, using popliteal lymph node assays in syngeneic
and F 1 recipients indicate similar levels of auto- and alloreactivity by cells from
drug-induced autoimmune donors. These various findings indicate that this
particular animal model may be useful for studies of the onset and control of
autoimmunity, and they raise the possibility that the lack of autoimmunity in
normal animals and its induction with cyclosporine may involve similar cellular
mechanism as have been found to be operative in GVH reactions and specifically
induced immunologic resistance to GVHD.
Received for publication 24July 1986.
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